Nature Communications (Jun 2017)

Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib

  • Thomas Lee Collier,
  • Marc D. Normandin,
  • Nickeisha A. Stephenson,
  • Eli Livni,
  • Steven H. Liang,
  • Dustin W. Wooten,
  • Shadi A. Esfahani,
  • Michael G. Stabin,
  • Umar Mahmood,
  • Jianqing Chen,
  • Wei Wang,
  • Kevin Maresca,
  • Rikki N. Waterhouse,
  • Georges El Fakhri,
  • Paul Richardson,
  • Neil Vasdev

DOI
https://doi.org/10.1038/ncomms15761
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 12

Abstract

Read online

Lorlatinib—a ROS1/ALK inhibitor—is currently undergoing clinical trials for the treatment of non-small cell lung cancers. Here the authors develop synthetic routes to11C- and 18F-labelled lorlatinib, with subsequent PET imaging showing good blood brain barrier permeability in non-human primates.